IMARC Group, a leading market research company, has recently releases report titled “Antisense & RNAi Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global Antisense & RNAi Therapeutics market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

How Big Is The Antisense & RNAi Therapeutics Market?

The global antisense & RNAi therapeutics market size reached US$ 1.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2028, exhibiting a growth rate (CAGR) of 8.3% during 2023-2028.

What are Antisense & RNAi Therapeutics?

Antisense therapy refers to the selective and sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. It regulates cell function and division and can modulate cellular responses to internal and external stresses and stimuli. In line with this, antisense therapy is also used to treat amyotrophic lateral sclerosis and Huntington's as well as Alzheimer's disease. On the other hand, RNA interference (RNAi) therapy is triggered by double-stranded RNA (dsRNA) and causes sequence-specific ribonucleic acid (mRNA) degradation of single-stranded target RNAs in response to dsRNA. Consequently, antisense and therapeutics are gaining extensive traction across the globe.

What Are The Growth Prospects And Trends In The Antisense & RNAi Therapeutics Industry?

The growing prevalence of chronic obstructive pulmonary disease (COPD), asthma, hereditary ATTR amyloidosis, etc., is primarily augmenting the antisense & RNAi therapeutics market. Furthermore, the escalating demand for disease management to regulate gene expression by malfunctioning genes is positively influencing the global market. Apart from this, the increasing usage of RNAi therapy to prevent the production of specific genes that cause diseases is acting as another significant growth-inducing factor. Moreover, the inflating need for curing and preventing cancer and human immunodeficiency virus (HIV) and continuous advancements in medical facilities are also bolstering the market growth. Besides this, the expanding healthcare sector across countries is further catalyzing the global market. Additionally, the rising investments in extensive R&D activities by key market players to develop molecules based on antisense technology and the strategic collaborations with contract research organizations (CROs) working on drug delivery are expected to fuel the antisense & RNAi therapeutics market in the coming years..    

What Is Included In Market Segmentation?

The report has segmented the market into the following categories:

Breakup by Technology:

  • RNA Interference
    • siRNA
    • miRNA
  • Antisense RNA

Breakup by Route of Administration:

  • Intravenous Route
  • Subcutaneous Route
  • Intrathecal Route
  • Pulmonary Delivery
  • Intraperitoneal Injection
  • Others

Breakup by Application:

  • Oncology
  • Cardiovascular Diseases (CVDs)
  • Respiratory Disorders
  • Renal Diseases
  • Neurodegenerative Disorders
  • Genetic Disorders
  • Infectious Diseases
  • Others

Breakup by End User:

  • Hospitals
  • Academic and Research Institutions
  • Ambulatory Surgical Centers
  • Diagnostic Laboratories
  • Others

Market Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

Who Are The Key Players Operating In The Industry?

The report covers the major market players including: 

  • Alnylam Pharmaceuticals Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals Inc.
  • Benitec Biopharma Ltd.
  • Bio-Path Holdings Inc.
  • Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
  • Ionis Pharmaceuticals Inc.
  • OliX Pharmaceuticals Inc.
  • Phio Pharmaceuticals Corp.
  • Sarepta Therapeutics Inc.
  • Silence Therapeutics
  • and Sirnaomics Inc.

Ask Analyst For Customization And Browse Full Report With TOC & List Of Figure: https://www.imarcgroup.com/antisense-rnai-therapeutics-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: [email protected]

Follow us on Twitter: @imarcglobal

LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/